CLEO has expanded its ovarian cancer Australian trial with the inclusion of the Royal Women’s Hospital as a participating site.

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) is pleased to confirm the commencement of U.S. clinical trials for its ovarian cancer diagnostic blood test.

Cleo Diagnostics Limited (ASX:COV) is pleased to announce progress for its U.S. clinical trials in support of its FDA application for its ovarian cancer diagnostic blood test.

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce progress in its regulatory strategy for its first commercial product, the pre-surgical triage test.

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) is pleased to announce the publication of a milestone article on its blood test for the accurate and early detection of ovarian cancer.

As a part of CLEO’s U.S. market access program, the Company will partner with U.S.-based CRO, Lindus Health, appointing it to manage the successful execution of its ovarian cancer U.S. clinical trials.

The U.S. represents CLEO’s largest market opportunity for its ovarian cancer blood test and is the focus for initial regulatory approval through the Food and Drug Administration (FDA).

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce the publication of further data on its triage test for ovarian cancer.

Cleo has completed the design transfer of the CXCL10 active ratio test into a more rigorous laboratory environment, ensuring the capability to deliver reproducible and reliable results.